Archive · 2026 · October 2026

Daily digest — 2026-10-08

2026-10-08

Four science items today: a dengue NS4B inhibitor design, a BBB-penetrant lanosterol derivative for Alzheimer's, chiral TLR7/8 imidazoquinolines and a PKMYT1 carboxamide patent overview. Business: Caribou's wind-down and AstraZeneca's new Kendall Square R&D site.

⚗️

Medicinal Chemistry

3 articles

2026-10-06 · ⚗️Aβ aggregation inhibitors (lanosterol derivatives) · Journal of Medicinal Chemistry (ACS)

Tuned lanosterol derivative crosses the BBB and curbs Aβ burden in AD mice

Natural productsNeuroscience

Lanosterol inhibits protein aggregation but has poor physicochemical and PK properties, so the authors tuned the hydrophilic–lipophilic balance around the 3-hydroxyl and the aliphatic side chain.
Systematic screening gave compound 10, with markedly better metabolic stability and drug-like properties.
Oral dosing of 10 rescued memory deficits and reduced Aβ burden in an Alzheimer's mouse model.

💡 Points

Natural-product sterols rarely survive their first PK table, so getting oral CNS exposure by tuning polarity around the 3-OH and side chain is the part I'd borrow. The open question is mechanism: efficacy in one mouse model is easy to over-read, and I'd want target engagement and sterol-pathway off-target data before getting excited.

Discovery of a BBB-Penetrant Lanosterol Derivative as an Aβ Aggregation Inhibitor for Alzheimer’s Disease ↗

2026-10-05 · ⚗️TLR7/8 modulators (imidazoquinolines) · ACS Medicinal Chemistry Letters (ACS)

Chiral imidazoquinolines show stereochemistry-dependent TLR7/8 agonism and antagonism

SAR & lead optimization Immune checkpoints & innate immunity

A library of chiral imidazoquinolines was made and profiled in HEK-Blue hTLR7 and hTLR8 reporter assays.
The SAR identified a potent dual TLR7/8 agonist and, from the same family, a dual antagonist.
Activity depended on stereochemistry, likely because the two enantiomers interact differently in the TLR7/8 binding pocket.

💡 Points

Seeing both an agonist and an antagonist come out of one imidazoquinoline family, steered by stereochemistry, is a good argument for making both enantiomers early. For an adjuvant or autoimmune program, that switch is useful, but reporter-cell data alone only gets it to a hit; cytokine profiling in primary cells would tell me whether it holds up.

Investigation of Chiral Imidazoquinoline Based Heterocyclic Small Molecules on TLR7/8 Modulatory Activity ↗

2026-10-05 · ⚗️PKMYT1 inhibitors (carboxamide series) · ACS Medicinal Chemistry Letters (ACS)

Patent highlight: carboxamide PKMYT1 inhibitors for replication-stress cancers

Kinases

PKMYT1 restrains CDK1 at the G2/M checkpoint, and blocking it forces premature mitotic entry, DNA damage accumulation and cancer cell death.
The patent overview covers the design, synthesis and therapeutic potential of a new carboxamide-based inhibitor series.
The authors note potential to enhance ATR inhibitors, PARP inhibitors, chemotherapy and radiotherapy.

💡 Points

This is patent-literature triage rather than data, so I read it as competitor intelligence: a carboxamide chemotype arriving in a PKMYT1 field already crowded with quinazolines says IP space is being carved up fast. I'd go straight to the examples to check the hinge binder and how hard the series leans on the PARP/ATR combination angle.

Novel Carboxamide-Based PKMYT1 Inhibitors for Replication Stress-Associated Cancers ↗

💻

Computational & AI

1 article

2026-10-06 · 💻Dengue virus NS4B inhibitors · Journal of Chemical Information and Modeling (ACS)

Modeling-led design yields a pan-serotype dengue NS4B inhibitor candidate

Structure-based designCheminformaticsInfectious disease

Comparative models of the structurally unresolved NS4B across all four dengue serotypes reveal a conserved transmembrane pocket that fits known resistance mutations.
Docking of the JNJ-series inhibitors fed predictive field-based 3D-QSAR models, which were used to screen bioisosteres and in-house compounds.
The top candidate, BNJ-495, was extremely potent against serotype 2 with a high selectivity index, and its conserved binding contacts suggest broad-spectrum activity.

💡 Points

A homology-model plus 3D-QSAR workflow that delivers a prospectively validated hit against a membrane protein with no structure is rare, and that is what makes this worth a look. Before I trust 'pan-serotype', I'd want to see the other three serotypes tested and whether the JNJ-series liabilities carried over.

Structure-Guided Design of a Subnanomolar Dengue Virus NS4B Inhibitor ↗

🏢

Industry News

2 articles

2026-10-07 · 🏢Discontinuation / wind-down · STAT News · Caribou Biosciences

Caribou Biosciences winds down after failing to fund late-stage CAR-T trial

Cell & gene therapy Oncology Financing & IPOs Restructuring & discontinuations

STAT reports the Doudna co-founded company is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma.
Other coverage describes the company stopping development of its two clinical cell therapy candidates and cutting most staff while exploring a merger or sale.
Only the public STAT+ summary was available, so details beyond that are unverified.

💡 Points

A flagship CRISPR-era CAR-T name folding over a funding gap says the off-the-shelf cell therapy thesis is struggling to raise money against autologous products and bispecifics. It reads more as a financing failure than a clean scientific verdict, so watch whether the assets and data find a buyer.

STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down ↗

2026-10-06 · 🏢R&D site opening / investment · STAT News · AstraZeneca

AstraZeneca opens $1B Kendall Square R&D site amid China dealmaking wave

China biotech

AstraZeneca opened a new R&D site in Boston's Kendall Square, marking a $1 billion investment.
STAT frames the opening against a backdrop of heavy dealmaking with Chinese biotechs and uncertainty in the US biotech hub.
Only the public STAT+ summary was available; site scope and headcount are not verified.

💡 Points

Planting a $1B flag in Kendall Square while licensing heavily from China looks like hedging: keep US discovery talent close even as external innovation shifts east. It's a capex signal, not a pipeline one, so the tell is whether the site hosts internal discovery or mostly integrates in-licensed assets.

STAT+: AstraZeneca opens new Boston site ↗